Chloé Beal

Chloé Beal

Auto-generated profile, based on publicly available information

Chloé Beal

Danone Research , Palaiseau

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2014 in The ISME Journal
Verified
Journal Article
Open access
PDF file
MRMichelle G Rooks
Michelle G Rooks
PVPatrick Veiga
Patrick Veiga
LWLeslie H Wardwell-Scott
Leslie H Wardwell-Scott
TTTimothy Tickle
Timothy Tickle
NSNicola Segata
Nicola Segata
WGWendy S Garrett
Wendy S Garrett
Dysregulated immune responses to gut microbes are central to inflammatory bowel disease (IBD), and gut microbial activity can fuel chronic inflammation. Examining how IBD-directed therapies influence gut microbiomes may identify microbial community features integral to mitigating disease and maintaining health. However, IBD patients often receive multiple treatments during disease flares, confounding such analyses. Preclinical models of IBD with well-defined disease courses and opportunities for controlled treatment exposures provide a valuable solution. Here, we surveyed the gut microbiome of the T-bet−/− Rag2−/− mouse model of colitis during active disease and treatment-induced remission. Microbial features modified among these conditions included altered potential for carbohydrate and energy metabolism and bacterial pathogenesis, specifically cell motility and signal transduction pathways. We also observed an increased capacity for xenobiotics metabolism, including benzoate degradation, a pathway linking host adrenergic stress with enhanced bacterial virulence, and found decreased levels of fecal dopamine in active colitis. When transferred to gnotobiotic mice, gut microbiomes from mice with active disease versus treatment-induced remission elicited varying degrees of colitis. Thus, our study provides insight into specific microbial clades and pathways associated with health, active disease and treatment interventions in a mouse model of colitis.

4 October 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
PVPatrick Veiga
Patrick Veiga
CGCarey Ann Gallini
Carey Ann Gallini
CBChloé Beal
Chloé Beal
MMMonia Michaud
Monia Michaud
MDMary L. Delaney
Mary L. Delaney
WGWendy S. Garrett
Wendy S. Garrett
Intestinal health requires the coexistence of eukaryotic self with the gut microbiota and dysregulated host-microbial interactions can result in intestinal inflammation. Here, we show that colitis improved in T-bet −/− Rag2 −/− mice that consumed a fermented milk product containing Bifidobacterium animalis subsp. lactis DN-173 010 strain. A decrease in cecal pH and alterations in short chain fatty acid profiles occurred with consumption, and there were concomitant increases in the abundance of select lactate-consuming and butyrate-producing bacteria. These metabolic shifts created a nonpermissive environment for the Enterobacteriaceae recently identified as colitogenic in a T-bet −/− Rag2 −/− ulcerative colitis mouse model. In addition, 16S rRNA-based analysis of the T-bet −/− Rag2 −/− fecal microbiota suggest that the structure of the endogenous gut microbiota played a key role in shaping the host response to the bacterial strains studied herein. We have identified features of the gut microbiota, at the membership and functional level, associated with response to this B. lactis -containing fermented milk product, and therefore this model provides a framework for evaluating and optimizing probiotic-based functional foods.